

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
天野 博雄	皮膚科学講座	教授	博士 (医学)	皮膚科学	① Prevalence and risk factors for onychomycosis in acute care dermatology wards. Inoue T, Watabe D, Furukawa M, Goto M, Kamada H, Sato Y, Arakawa N, Miura S, Sato T, Yasuhira S, Tsunemi Y, Amano H. J Dermatol. 2024;51:1079-1082. ② Outcome of fosravuconazole treatment for onychomycosis refractory to topical antifungal agents. Inoue T, Watabe D, Tsunemi Y, Amano H. J Dermatol. 2023;50(8):1014-1019. ③ DUSP4 inactivation leads to reduced extracellular signal-regulated kinase activity through upregulation of DUSP6 in melanoma cells. Kamada H, Yasuhira S, Shibazaki M, Amano H, Maesawa C. J Invest Dermatol. 2022;142(9):2499-2507. ④ Successful treatment of squamous cell carcinoma on the lip with continuous intra-arterial peplomycin infusion chemotherapy: a report of 27 cases. Onishi M, Takahashi K, Maeda F, Akasaka T, Amano H. Eur J Dermatol. 2022;32(2):287-289. ⑤ Hair abnormality in Netherton syndrome observed under polarized light microscopy. Utsumi D, Yasuda M, Amano H, Suga Y, Seishima M, Takahashi K. J Am Acad Dermatol. 2020;83(3):847-853.
渡部 大輔	皮膚科学講座	准教授	博士 (医学)	皮膚科学	①Development of psoriasis during obinutuzumab treatment in a patient with follicular lymphoma. Watabe D, Amano H. J Dermatol. 2024;51(11) e404-e405. ②Unilateral lymphedema after second dose of BNT162b2 COVID-19 mRNA vaccine. Watabe D, Amano H. Eur J Dermatol. 2023;33(3):312-314. ③A severe case of primary erythromelalgia presenting as small fiber neuropathy with a novel SCN9A mutation. Watabe D, Tominaga M, Toyama S, Takamori K, Nakano H, Amano H. J Dermatol. 2023;50(7):938-941 ④TNF- α inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis. Watabe D, Amano H. Eur J Dermatol. 2021;31(3):412-413. ⑤Development of psoriasis during docetaxel therapy in a patient with non-small-cell lung cancer. Watabe D, Amano H. J Dermatol. 2020;47(12):e427-e428.
角田 加奈子	皮膚科学講座	講師	博士 (医学)	皮膚科学	①Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series. Tsunoda K, Watabe D, Amano H. JAAD Int. 2024;16:57-58. doi: 10.1016/j.jdin.2024.03.017. ②Exacerbation of psoriasis following vaccination with the Pfizer-BioNTech BTN162b2 mRNA COVID-19 vaccine during risankizumab treatment. Tsunoda K, Watabe D, Amano H. J Dermatol. 2023;50(2):e79-e80. ③Erythromelanositis Follicularis Faciei et Colli Treated With Intense Pulsed Light. Tsunoda K, Watanabe A, Amano H. Dermatol Surg. 2022 May 1;48(5):588-589. doi: 10.1097/DSS.0000000000003382. ④【科研費】乳房外Paget病におけるCOX2, HDAC6の相互作用の解析 若手研究 2019-04-01-2021-03-31 ⑤【科研費】次世代シーケンサーによる多能性維持転写因子NACC1制御下遺伝子の網羅的同定 若手研究(B) 2013-04-01-2016-03-31

渡辺 彩乃	皮膚科学講座	講師	博士 (医学)	皮膚科学	①Case report of meningeal carcinomatosis in advanced cutaneous apocrine carcinoma. Watanabe A, Tsunoda K, Watabe D, Sugai T, Amano H. J Dermatol. 2021;48(10):E504-E505. ②Meningeal carcinomatosis in advanced extramammary Paget's disease: a case report. Watanabe A, Onishi M, Tsunoda K, Amano H. Acta Derm Venerol. 2019;99(9):826-827. ③BCL2 and BCLxL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells Ayano Watanabe , Shinji Yasuhira, Tsuyoshi Inoue, Shuya Kasai, Masahiko Shibazaki, Kazuhiro Takahashi, Toshihide Akasaka, Tomoyuki Masuda, Chihaya Maesawa Exp Dermatol. 2013;22(8):518-23. ④全身性エリテマトーデスとシェーグレン症候群の合併例に生じた多発性皮膚線維腫 渡辺彩乃、鎌田啓文、渡部大輔、天野博雄 皮膚病診療 2020;42(5):394-397 ⑤【科研費】悪性黒色腫に対する人血清アルブミン結合型微小管阻害薬の作用増強に係る基礎研究 若手研究(B) 2015-04-01-2017-03-31
三浦 慎平	皮膚科学講座	講師	博士 (医学)	皮膚科学	①Lower limb ulcers due to an absent inferior vena cava. Miura S, Watanabe A, Amano H. JAAD Case Rep. 2022;21:87-89. ②Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas. Miura S, Maesawa C, Shibazaki M, Yasuhira S, Kasai S, Tsunoda K, Maeda F, Takahashi K, Akasaka T, Masuda T. Am J Dermatopathol. 2014;36:211-216. ③Conjunctival Malignant Melanoma Treated Successfully with BRAF Inhibitor: Encorafenib plus Binimetinib. Miura S, Onishi M, Watabe D, Amano H. Dermatol Online J. 2022; Jan 15;28(1). doi: 10.5070/D328157075. ④【科研費】正常メラノサイトにおけるK E A P 1突然変異の悪性黒色腫発生リスク増加に関する研究 若手研究(B) 研究期間 2014-04-01-2016-03-31 ⑤A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance. Miura S, Shibazaki M, Kasai S, Yasuhira S, Watanabe A, Inoue T, Kageshita Y, Tsunoda K, Takahashi K, Akasaka T, Masuda T, Maesawa C. J Invest Dermatol. 2014;134:553-556.
井上 剛	皮膚科学講座	助教	博士 (医学)	皮膚科学	①Inoue T., Watabe D., Furukawa M., Goto M., Kamada H., Sato Y., Arakawa N, Miura S., Sato T., Yasuhira S., Tsunemi Y., Amano H. : Prevalence and risk factors for onychomycosis in acute care dermatology wards / J Dermatol.51:1079-1082 (2024) ②Inoue,T., Watabe,D., Tsunemi Y, Amno H. : Outcome of fosravuconazole treatment for onychomycosis refractory to topical antifungal agents / J Dermatol.50:1014-1019 (2023) ③Inoue,T., Watabe,D., Akasaka K, Sasaki T, Sasahara Y, Amno H.: Refractory atopic dermatitis in a child with hypomorphic mutation in XIAP gene and low serum IgG / J Dermatol.DOI: 10.1111/1346-8138.16869 ④井上剛：多形慢性痒疹. 皮膚疾患最新の治療2025-2026（高橋健造 佐伯秀久 編）. 南江堂.41（2025） ⑤帯状疱疹関連痛における漢方薬の役割. 井上 剛、天野博雄. Progress in Medicine 2020;9:77-81.